Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23810206 | 0.83 | KDM4E (0.41) | KDM4ENPC1RAB9AKDM4CAPOBEC3A | |
| SCHEMBL22122703 | 0.82 | GRM5 (0.38) | GRM5EPHX2NAMPTKDM4ENPC1 | |
| SCHEMBL16560328 | 0.78 | KDM4E (0.41) | EPHX2KDM4ELMNANPC1RAB9A | |
| SCHEMBL15285036 | 0.76 | MAOB (0.44) | EPHX2KDM4ENPC1RAB9AKDM4C | |
| SCHEMBL23810201 | 0.76 | KDM4E (0.45) | KDM4ENPC1RAB9AKDM4CAPOBEC3A | |
| SCHEMBL22149715 | 0.75 | KDM4E (0.40) | KDM4ENPC1RAB9AKDM4CAPOBEC3A | |
| SCHEMBL23810141 | 0.74 | KDM4E (0.40) | KDM4ENPC1RAB9AKDM4CAPOBEC3A | |
| SCHEMBL19308748 | 0.74 | KMT2A (0.39) | KDM4ENPC1RAB9AKDM4CAPOBEC3A | |
| SCHEMBL20804067 | 0.73 | KDM4E (0.38) | KDM4ELMNANPC1RAB9AKDM4C | |
| SCHEMBL23255193 | 0.73 | SMN1; SMN2 (0.39) | KDM4ENPC1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300896-A1 | HETEROCYCLIC AZIDE UNITS AND THEIR USE IN POLYMER COATINGS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-11999696-B2 | Heterocyclic azide units and their use in polymer coatings | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| CN-112672996-B | Heterocyclic azide units and their use in polymeric coatings | 伊鲁米纳剑桥有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20210284609-A1 | HETEROCYCLIC AZIDE UNITS AND THEIR USE IN POLYMER COATINGS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| CN-112672996-A | Heterocyclic azide units and their use in polymeric coatings | 伊鲁米纳剑桥有限公司 | 2021-04-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300896-A1 | HETEROCYCLIC AZIDE UNITS AND THEIR USE IN POLYMER COATINGS | POLL, PCNA, DNMT3A | GRM5 2711/4885EPHX2 2220/4885NAMPT 3200/4885 |
| US-20210284609-A1 | HETEROCYCLIC AZIDE UNITS AND THEIR USE IN POLYMER COATINGS | POLL, PCNA, DNMT3A | GRM5 2711/4885EPHX2 2220/4885NAMPT 3200/4885 |
| US-11999696-B2 | Heterocyclic azide units and their use in polymer coatings | POLL, PCNA, DNMT3A | GRM5 2711/4885EPHX2 2220/4885NAMPT 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.